STOP-HCC Evidence-Based Hepatocellular Cancer Prevention Through Treatment of Hepatitis C Virus Infection
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 12,386
- Locations
- 1
- Primary Endpoint
- Hepatitis C Screening
Study Overview
Brief Summary
Aim 1: The investigators will conduct a randomized controlled trial comparing two strategies to promote HCV screening, follow-up testing, and treatment among baby-boomers (i.e. persons born between 1945-1965): inreach with electronic medical record alerts and provider education vs. combination of inreach and provider education plus mailed outreach and patient navigation.
Aim 2: The investigators will evaluate patient navigation strategies to promote follow-up testing and treatment evaluation among non-baby boomer Parkland patients (i.e. born before 1945 or after 1965) who are either: a) HCV antibody positive but have not completed follow-up viral load testing or b) HCV viral load positive and who have not completed in-clinic treatment evaluation.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Screening
- Masking
- Double (Care Provider, Outcomes Assessor)
Eligibility Criteria
- Ages
- 53 Years to 74 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •born between 1945 and 1965
- •≥ 1 outpatient visit during 12 months prior to randomization at Parkland
- •no prior HCV screening (prior HCV antibody, viral load, or genotype).
- •any active medical coverage
- •speaks Spanish or English
Exclusion Criteria
- •a life expectancy less than one year including end stage CHF, end stage COPD, metastatic cancer, and those who received a palliative care or hospice referral in the past year
- •history of HCC.
- •non-English or Spanish speakers
- •no address or phone number on file
Arms & Interventions
Usual Care
Patients randomized to Group 1 will receive visit-based HCV screening, as offered by clinic providers as part of usual care. Providers must identify at-risk patients who are eligible for HCV screening, understand the benefits of screening in this population, and enter orders for HCV Ab testing. If the HCV antibody is abnormal, providers must order appropriate follow-up tests including HCV viral load to confirm HCV infection. Once HCV is confirmed, providers must refer the patients for fibrosis assessment and treatment evaluation. These efforts are augmented by an established best practice alert and health maintenance reminders.
Mailed outreach
Patients randomized to Group 2 will receive low literacy, written materials about HCV screening among baby-boomers in English and Spanish. The invitation will include patient-centered educational materials that discuss the risk of HCV in baby boomers and the benefits and risks of HCV screening. The invitation will include a phone number to schedule the HCV antibody blood test. Written materials will be developed and validated in Spanish using the Spanish Language Translation Resource. Once a potential subject is identified and randomized in Group 2, an outreach invitation will be mailed out. Shortly after the letter, a bilingual patient navigator will place a follow-up call to this potential subject. These follow-up calls will occur in the 2nd - 4th week after mailing invitations; up to three attempts in total will be made to reach the patient to facilitate HCC screening completion.
Intervention: Mailed outreach (Behavioral)
Outcomes
Primary Outcomes
Hepatitis C Screening
Time Frame: 3 months
Proportion with HCV Ab within 3 months of randomization
Secondary Outcomes
- Hepatitis C Linkage to care(6 months)
- Cost: Cost-per patient screened(3 months)
- Cost: Cost per-HCV diagnosis(12 months)
- Hepatitis C Confirmation(3 months)
- Hepatitis C Screening(12 months)
Investigators
Amit Singal
Principal Investigator
University of Texas Southwestern Medical Center